Free Trial
OTCMKTS:TBIO

Telesis Bio Earnings Date & Estimates

Telesis Bio logo
$0.01 0.00 (0.00%)
As of 11/9/2026 03:24 PM Eastern

Telesis Bio is estimated to report earnings on Tuesday, November 17, 2026.

What Analysts Expect from Telesis Bio

Telesis Bio is expected to post earnings of -$6.39 per share on revenue of $2.53 million. Telesis Bio has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$6.39
Expected Revenue
$2.53 million

Recent Track Record

Last Reported
Q3 2024
Last Quarter EPS
-$3.83
Last Quarter Revenue
$1.57 million
EPS Beat Rate
6 of last 8 quarters

Telesis Bio Earnings FAQ

Telesis Bio (OTCMKTS:TBIO) is estimated to report earnings on Tuesday, November 17, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Telesis Bio to post earnings of -$6.39 per share for the quarter.

The consensus revenue estimate for Telesis Bio is $2.53 million for the quarter.

Telesis Bio Earnings Headlines

Telesis Bio, Inc. Common Stock (TBIO)
Executive Order 14241 Unleashes Trump’s New Dollar
A landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December. The agenda at the upcoming G20 Summit in Miami has shifted, and new research points to a major monetary announcement from President Trump. A new documentary breaks down what this shift could mean for savings, investments, and the assets tied to it.tc pixel
Telesis Bio Inc.
See More Telesis Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Telesis Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Telesis Bio and other key companies, straight to your email.

About Telesis Bio

Telesis Bio (OTCMKTS:TBIO) develops automated synthetic biology systems designed to help researchers create and test biological molecules more efficiently. Its technology is intended to streamline the design-build-test process by automating tasks that traditionally require multiple manual laboratory steps.

The company’s primary products include the BioXp automated benchtop platforms and related consumables, software, and application-specific kits. These systems support the on-demand synthesis and assembly of DNA, messenger RNA and other biological constructs for applications such as gene and cell therapy research, vaccine development, protein engineering, diagnostics and synthetic biology.

Telesis Bio was formerly known as Codex DNA and changed its corporate name in 2023. The company markets its products to biotechnology and pharmaceutical companies, academic and government research institutions, and other life sciences organizations. Its platform is designed for use by customers in research and development laboratories in the United States and international markets.

View Telesis Bio Profile